Abstract
There is no consensus regarding chemotherapy to patients with advanced NSCLC (ANSCLC) and performance status (PS) 2. Using data from a national multicenter study comparing two third-generation carboplatin-based regimens in ANSCLC patients, we evaluated the outcome of PS 2 patients. The 123 PS 2 patients were compared to 309 PS 0/1 patients regarding survival, quality of life (QOL) and treatment toxicity. PS 2 patients had lower haemoglobin, lower global QOL and more pain, nausea/vomiting and dyspnea at inclusion. 68% of PS 2 patients received three chemotherapy courses vs. 85% in the PS 0/1 group (P<0.01). Median and 1-year survival were lower in the PS 2 group, 4.5 vs. 8.9 months and 10% vs. 37% (P<.01). More PS 2 patients needed blood transfusions (P=0.03) and hospitalization (P<0.01). In contrast, PS 2 patients had better relief of pain and dyspnea, and tended to a better global QOL and did not experience more leucopoenia, infections or bleeding. Despite shorter survival, treatment toxicity was acceptable and PS 2 patients achieved better improvement of pain and dyspnea and tended to better global QOL when compared to PS 0/1 patients.
References
Sep 1, 1992·Cancer·H BülzebruckI Vogt-Moykopf
Jan 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C RuckdeschelS Vogl
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Mar 3, 1993·Journal of the National Cancer Institute·N K AaronsonJ C de Haes
Dec 18, 2001·Cancer·C J SweeneyD H Johnson
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paris KosmidisMeletios Dimopoulos
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V AlberolaUNKNOWN Spanish Lung Cancer Group
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Egbert F SmitUNKNOWN European Organization for Research and Treatment of Cancer Lung Cancer Group
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C GridelliF De Marinis
Dec 16, 2004·Seminars in Oncology·Karen Kelly
Dec 22, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francesco PerroneCesare Gridelli
Dec 28, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Thomas E StinchcombeMark A Socinski
Feb 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Corey LangerUNKNOWN Eastern Cooperative Oncology Group
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Paris A KosmidisHaralampos P Kalofonos
Jun 7, 2007·Journal of the National Cancer Institute·Andrea ArdizzoniUNKNOWN CISCA (CISplatin versus CArboplatin) Meta-analysis Group
Aug 11, 2007·The European Respiratory Journal·J P SculierUNKNOWN European Lung Cancer Working Party
Citations
Jun 18, 2010·Cancer Chemotherapy and Pharmacology·Yasunari OkiMitsuru Adachi
Oct 1, 2010·Der Schmerz·B Alt-Epping, F Nauck
Jun 13, 2009·Japanese Journal of Clinical Oncology·Young Hak KimYutaka Nishiwaki
Mar 2, 2011·Journal of Oncology Practice·Shalini K VinodGeoff P Delaney
Jul 23, 2014·The Journal of Molecular Diagnostics : JMD·Yi-Lin ChenChung-Liang Ho
Mar 29, 2013·Medical Oncology·Stéphane JouveshommeSylvie Bastuji-Garin
Jan 28, 2014·Cell Biochemistry and Biophysics·Gang TianXiaogang Xu
Mar 11, 2009·Acta Oncologica·Nina HelbekkmoUNKNOWN Norwegian Lung Cancer Study Group
Nov 4, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Dale HardyXianglin L Du
Oct 10, 2015·Cancer·Michael KollerUNKNOWN EORTC Lung Cancer Group